iCAD (NASDAQ:ICAD) Raised to “Hold” at StockNews.com

StockNews.com upgraded shares of iCAD (NASDAQ:ICAD) from a sell rating to a hold rating in a research note issued to investors on Thursday morning.

iCAD Price Performance

Shares of NASDAQ:ICAD opened at $1.54 on Thursday. iCAD has a 52-week low of $1.18 and a 52-week high of $2.65. The company has a 50 day moving average of $1.72 and a two-hundred day moving average of $1.54. The company has a market capitalization of $40.87 million, a price-to-earnings ratio of -11.85 and a beta of 1.47.

Institutional Investors Weigh In On iCAD

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ICAD. Perritt Capital Management Inc. boosted its position in iCAD by 7.5% in the 1st quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company’s stock valued at $225,000 after buying an additional 9,717 shares during the last quarter. Virtu Financial LLC boosted its holdings in iCAD by 55.6% in the first quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock valued at $34,000 after purchasing an additional 7,604 shares during the last quarter. Perritt Capital Management Inc boosted its holdings in iCAD by 14.2% in the second quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock valued at $208,000 after purchasing an additional 19,917 shares during the last quarter. Finally, Essex LLC acquired a new stake in iCAD during the 3rd quarter valued at approximately $216,000. Hedge funds and other institutional investors own 24.61% of the company’s stock.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.